On February 3, 2022, the first participant was treated in the MAPS-sponsored Phase 2, open-label study of the comparative effectiveness of two vs. three MDMA-assisted therapy sessions in Veterans with PTSD at the James J. Peters Veterans Affairs (VA) Medical Center in Bronx, New York. The study is expected to treat up to 60 participants over 2-3 years.
